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Heterotrimeric G proteins play an essential role in the initia-
tion of G protein-coupled receptor (GPCR) signaling through
specific interactions with a variety of cellular effectors.We have
recently reported that GPCR activation promotes a direct inter-
action between Gq and protein kinase C  (PKC), leading to
the stimulation of the ERK5 pathway independent of the canon-
ical effector PLC. We report herein that the activation-depen-
dent Gq/PKC complex involves the basic PB1-type II domain
of PKC and a novel interaction module in Gq different from
the classical effector-binding site. Point mutations in this Gq
region completely abrogate ERK5 phosphorylation, indicating
that Gq/PKC association is required for the activation of the
pathway. Indeed, PKC was demonstrated to directly bind ERK5
thus acting as a scaffold betweenGq and ERK5 uponGPCR acti-
vation. The inhibition of these protein complexes by G protein-
coupled receptor kinase 2, a knownGqmodulator, led to a com-
plete abrogation of ERK5 stimulation. Finally, we reveal that Gq/
PKC complexes link Gq to apoptotic cell death pathways. Our
data suggest that the interaction between this novel region inGq
and the effector PKC is a key event in Gq signaling.
G-protein-coupled receptors (GPCRs)5 are the largest and
most versatile family of transmembrane receptors (1). Particu-
larly, Gq-coupled GPCRs mediate the action of many hor-
mones and neurotransmitters with a paramount role in health
and disease. Gq activates phospholipase C (PLC) isoforms,
which hydrolyze PIP2 leading to protein kinase C (PKC) activa-
tion and Ca2 mobilization (2). However, a growing body of
evidence suggests that alternative effectors underlie additional,
PLC-independent functions of Gq. Thus, p63RhoGEF (3)
directly binds to Gq/11 linking GPCRs and RhoA activation.
The competition betweenPLC and p63RhoGEF for binding to
Gq indicates the existence of alternative and mutually exclu-
sive Gq-initiated pathways (4). Indeed, all characterized Gq
effectors have been shown to bind to the same region, which
comprises the C-terminal half of the 2 helix (Switch II)
together with the 3 helix and its junction with the 5 strand
(5). Additionally, the GPCR receptor kinase (GRK) 2 acts as
negative regulator of Gq function by shielding this surface
away from effectors (6).
Mitogen-activated protein kinases (MAPKs) are essential
downstream targets inG protein pathways.MAPKs control key
cellular functions, including proliferation, differentiation,
migration and apoptosis, and participate in a number of disease
states including chronic inflammation and cancer (7). Recently
we have described a novel signaling axis for the activation of
ERK5 MAPK by Gq-coupled GPCRs in epithelial cells that is
independent of PLC and relies on a previously unforeseen role
of Gq as an adaptor protein through direct associations with
two novel binding partners, PKC andMEK5 (8). Subsequently,
this novel activation mechanism for ERK5 was shown to be
conserved in cardiac cells and the physiological relevance of the
Gq/PKC/ERK5 pathway in the development of cardiac hyper-
trophy programs was established using PKC-deficient mice
(9). In the present work we have characterized the architecture
of the Gq/PKC complex in the context of the ERK5 pathway
and determined that a novel interaction region underlies the
ability of Gq to trigger the PKC/ERK5 cascade and to pro-
mote apoptotic cell death.
Experimental Procedures
Materials—The cDNAs of Gq, Gq-R183C, and Gq-
Q209L were kindly provided by Dr. A. Aragay (CSIC, Barce-
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lona, Spain). The constitutively active Gqmutant protein that
lacks the ability to interact with PLC (Gq Q209L/R256A/
T257A) was provided by Dr. Richard Lin (Stony Brook Univer-
sity, New York). The cDNAs encoding HA-PKC, GST-MEK5,
and HA-ERK5 have been previously described (8). The cDNAs
encoding Gq/Gi1 chimeras (Gi-ctGq, Gq-ctGi) were a
kind gift from Dr. C. H. Berlot (Weis Center for Research).
GRK2 wt and GRK2-D110A were a gift from Dr. J. L. Benovic
(Thomas Jefferson University, Philadelphia, PA), GRK2-Y261F
and W263D were a gift from Dr. T. Kozasa (University of
Illinois at Chicago), the RH domain andRGS2/4were fromDr.
A. de Blasi (University of Rome “Sapienza”, Italy), and the
PKC-PB1 domain was described previously (8). Recombi-
nant GST-ERK5 was obtained from Sigma-Aldrich. Recombi-
nant His6-PKC was provided by Dr. Moscat (Sanford-Burn-
ham Medical Research Institute, La Jolla, CA). and by Dr.
James Hastie (Division of Signal Transduction Therapy,
School of Life Sciences, MSI/WTB/JBC Complex, University
of Dundee, Scotland). PKC-targeting and scrambled
shRNA were from Sigma-Aldrich.
CHO cells overexpressing the muscarinic M3 acetylcholine
receptor, designated CHO-M3 cells, were a kind gift from Dr.
A. B. Tobin (University of Leicester, UK). COS-7, HeLa, and
HEK293 cells were from theAmericanTypeCulture Collection
(ATCC, Manassas, VA). Culture medium and Lipofectamine
were from Life Technologies Inc. (Gaithersburg, MD). The
affinity-purified mouse monoclonal antibody against Gq was
from Abnova (Walnut, CA). The polyclonal antibodies
against Gq (C-19), GRK2 (C-15), ERK1 and ERK2 and GST
were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Monoclonal antibodies against HA tag and Glu-Glu (EE) tag
were from Covance. The anti-phospho-ERK5 antibody (p-
Thr218/p-Tyr220) was purchased from Invitrogen (Carlsbad,
CA). Anti-ERK5 and anti-phospho ERK1/2 antibodies, anti-
PKC, and anti-cleaved caspase-3 (Asp175) were fromCell Sig-
naling (Beverly, MA). Anti--tubulin was from Sigma. The
anti-GRK2 antibody that recognizes the N terminus of GRK2
was generated in our laboratory. Protein-G Sepharose was
obtained from Invitrogen. Carbachol was from Sigma. All other
reagents were of the highest commercially available grades.
Cell Line Culture and Treatments—CHO cells were main-
tained in MEM and HeLa, COS-7, and HEK293 cells were
maintained in DMEM supplemented with 10% (v/v) bovine
serum (Sigma-Aldrich, St. Louis, MO) at 37 °C in a humidified
5% CO2 atmosphere. The desired cell type was stimulated with
carbachol at 37 °C in serum-freemedium, at the specified doses
and during the indicated time periods. The cells were serum-
starved before ligand addition to minimize basal kinase
activity. When required, cells (70–80% confluent monolay-
ers in 60-mm dishes) were transiently transfected with the
desired combinations of cDNA constructs using the Lipo-
fectamine/Plus method (Invitrogen), following manufacturer’s
instructions. Empty vector was added to keep the total amount
of DNA per dish constant. Assays were performed 24 h after
FIGURE 1. Gq and PKC interaction in vitro and in living cells. A, PKC preferentially binds the GTPS loaded form of Gq. 20 nM of purified His-PKCwas
incubated with purified Gq or Gq loaded with GTPS as detailed under “Experimental Procedures.” B and C, Gq/PKC complex selectivity in living cells. B,
schemeof theProtein-fragmentComplementationAssay (PCA, see “Experimental Procedures”). Fluorescenceuponexpressionof theproteinpair in living cells
is ameasure of the occurrence of an interaction between these proteins. The irreversible nature of fluorescent protein YFP-PCA assays allow for easy trapping
and visualization of transient complexes. C, CHO-M3 cells were transfectedwith different pairs of PCA plasmids that express proteins fused to complementary
N- and C-terminal fragments of Venus-YFP: Control (PKC-Venus YFP[F1] pcDNA3), ZipperZipper (Zipper-Venus YFP[F1] Zipper Venus YFP[F2]), Gq
PKC (Gq-Venus YFP[F1] PKC-Venus YFP[F2]), GqPKC (Gq-Venus YFP[F1] PKC-Venus YFP[F2]), PKC Gi (Gi-Venus YFP[F1] PKC-Venus
YFP[F2]). Representative bright field and YFP images at 40 magnification are shown. Bar length, 25 m. Fluorometric analysis was performed, and data
(mean S.E. of three independent experiments) were normalized with respect to control (***, p 0.001, two tailed t test).
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transfection. Transient expression of the desired proteins was
confirmed by immunoblot analysis of whole-cell lysates using
specific antisera.
Cloning and Mutagenesis—Venus-YFP expression con-
structs for the protein complementation assay (PCA) were ob-
tained by sub-cloning Gnaq (mouse, accession number NM_
002072) and Prkcz (rat, accession number NM_022507.1) into
the 5- and 3-ends of the Venus YFP PCA fragments, referred
to here as N-terminal fragment (1–158 aa; F[1]) and the C-ter-
minal fragment (159–239 aa; F[2]), respectively, as previously
described (10). PKC binding-deficient mutants, Gq binding-
deficient mutants and Gq constitutively active mutants were
prepared using the QuickChange site-directed mutagenesis kit
(Stratagene) followingmanufacturer’s instructions.
Co-immunoprecipitation Assays—24–48 h after transfec-
tion, cells were scraped and washed twice with ice-cold phos-
phate-buffered saline, solubilized in RIPA buffer (50 mM Tris,
pH 7.5, 150 mM NaCl, 0.5% (w/v) sodium deoxycholate, 1%
(w/v) Triton X-100, 0.1% SDS, protease inhibitors), and clari-
fied by centrifugation. Immunoprecipitation was performed
with agarose-conjugated anti-HA antibodies (Santa Cruz Bio-
technology, F-7) or, alternatively, with 1 mg/ml bovine serum
albumin and anti-Gq (Santa Cruz Biotechnology, C19) fol-
lowed by re-incubation with protein G-Sepharose. All blots
were developed using the chemoluminescence method and
quantified by laser-scanner densitometry.
Pull-down Assays—To analyze MEK5/PKC binding, lysates
from cells expressing GST-MEK5 (or GST alone as a negative
control) were subjected to GST pull-down assays with glutathi-
one-Sepharose 4B as previously reported (8). In the analysis of
PKC-ERK5 binding, purified GST-ERK5 or GST were incu-
bated overnight at 100 nMwith 20 nMHis-PKC at 4 °C in bind-
ing buffer (50 mM Tris-HCl, pH 7.9, 0.01% Lubrol, 0.6 mM,
EDTA, and 70 mM NaCl) supplemented with a protease inhib-
itor mixture. Fusion proteins were incubated for 2 h at 4 °C with
glutathione-Sepharose 4B beads and washed 8–10 times with the
samebuffer. To explorewhetherPKCbinds toGq in aGTP-de-
pendentmanner, 20nMof purifiedHis6-PKCwas incubatedwith
Ni-NTA resin (Probond) for 2 h at 4 °C in His-Binding Buffer (20
mMTris-HCl, pH 7.9, 100mMNaCl, 10mM imidazole). Themix-
turewas then incubatedwith50nMofpurifiedGqorGq loaded
with GTPS overnight at 4 °C in the same buffer. Recombinant
protein complexes were washed 8–10 times with His-Binding
Buffer supplemented with 30mM imidazole.
Preparation of Gq-GTPS—Recombinant Gq was purified
as described (11). Gq-GDP (10 M) was incubated in a 1 ml
reaction with 20 M purified Ric-8A (12) and 100 M GTPS
in 20 mM Hepes, pH 8.0, 100 mM NaCl, 0.05% Genapol C-100,
10 mM MgCl2, 1 mM EDTA, 2 mM DTT for 1 h at 25 °C. The
reaction was gel filtered over Superdex 75/200 columns
arranged in series to separate Gq from Ric-8A. The mono-
meric Gq-GTPS fractions were pooled, concentrated in a
10,000 MWCO Amicon Ultracentrifugal device, and stored as
20-M aliquots at80 °C.
Determination of ERK5 MAPK Stimulation—Lysates were
resolved by 8% SDS-PAGE and subjected to immunoblot anal-
FIGURE 2. PKC interacts with Gq through its PB1-type II domain. A, overexpression of PKC-PB1 domain interferes with Gq/PKC association. B, Gq
co-immunoprecipitates with the PKC-PB1 domain. In both panels COS-7 cells were transfected with the indicated plasmids and co-immunoprecipitation
assaysperformedasdescribedunder “Experimental Procedures”.C, cartoonof thePB1 type II domainof PKC. Selected residues (*), homologous to interaction-
driving amino acids in other PB1-type II proteins (18), weremutated to alanine.D, mutations in PKCPB1-type II domain interferewithGqbinding. COS-7 cells
were transfected with Gq and different HA-PKCmutants and subjected to co-immunoprecipitation analysis as above. Data (mean S.E. of three indepen-
dent experiments) were normalized with respect to Gq/PKCwt association (*, p 0.05; **, p 0.005, two tailed t test). E, lysine 19 in the PB1-type II domain
of PKC is essential for MEK5 binding. COS-7 cells transfected with different combinations of plasmids encoding MEK5-GST, HA-PKC, and HA-PKCK19A and
pull-downs and total lysates analyzed as in panel B. F, a mutation in the PB1-type II domain of PKC enhances the interactionwith Gq. COS-7 cells transfected
with Gq and wild-type or HA-PKC-H21A mutant constructs were analyzed as in panels above. To compare the association of Gq with the PKCmutant,
immunoblotted protein bandswere quantified and normalized by total HA-PKC. Data (mean S.E. of three independent experiments) were normalizedwith
respect to Gq/PKCwt association. (**, p 0.005, two tailed t test). Blots representative of three independent experiments are shown in all panels.
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ysis as previously described (8). The activation state of ERK5
was measured by laser-scanner densitometry and expressed as
the amount of phospho-ERK5 normalized to the amount of the
total ERK5 protein. In CHO and HeLa cell lines HA-tagged
ERK5 was transfected and immunoprecipitated with anti-HA
agarose beads (Santa Cruz). Immunoprecipitates were washed
in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% (w/v) Non-
idet P-40, 0.25% (w/v) sodiumdeoxycholate, 1mMEGTA, 1mM
NaF, supplemented with 1 mM sodium orthovanadate plus a
mixture of protease and phosphatase inhibitors) at 4 °C.
Protein-fragment Complementation Assays (PCA)—Protein-
protein complexes can be recapitulated in living cells, by fusing
protein pairs to complementary N- and C-terminal fragments
of a reporter (enzyme or fluorescent protein). If the proteins
interact the fragments of the reporter protein will be brought
into proximity where they can spontaneously fold together and
reconstitute enzymatic activity or fluorescence (10). Venus
YFP-based PCA: Cells were co-transfected with the Venus YFP
PCA expression vectors coding for prey-F[1] and/or bait-F[2].
Twenty-four hours after transfection, cells were subjected to
fluorometric analysis and fluorescence microscopy. For the
fluorometric analysis, cells were trypsinized and resuspended
in PBS, transferred to 96-well black microtiter plates (Dynex;
VWR Scientific, Mississauga, Ontario), and measured in a flu-
orometer (integration time 10 s, excitation wavelength 470 nm,
emission wavelength 528 nm) (Spectra MAX GEMINI XS;
Molecular Devices, Sunnyvale, CA). Background fluorescence
was subtracted from fluorometric values of all of the samples.
Fluorescencemicroscopy was performed using a Nikon Eclipse
TE2000U inverted microscope with 40 objective and YFP fil-
ter cube (41028, Chroma Technologies). Images were captured
with a CoolSnap CCD camera (Photometrics) using Meta-
morph software (Molecular Devices). When comparing differ-
ent PCA pairs, identical microscopy settings were utilized, and
the expression of each construct was assessed by Western blot
to ensure that the differences observed in the fluorescence
images was a due to a lack of interaction and not to insufficient
expression of one of the reporters.
xCELLigence Measurements—The xCELLigence system RTCA
SP instrument (Roche Applied Science) monitors changes in
the cell index (a measure of cell attachment to the plate), which
has been shown to effectively correlate to proliferation, adhe-
sion, and viability changes (13, 14). To assess long-termviability
cells were seeded in 96-well gold electrode sensor plate
(E-plates) pre-coated with fibronectin (10 M) and monitored
every 15 min for at least 3 days in minimal medium (3% FBS)
until an irreversible decrease (inflection point) in the cell index
was recorded. Cell death was expressed as the time between the
start of the experiment and the inflection point. The first 16 h
after the cells were plated were excluded from each analysis as
they correspond to the cell adhesion phase. In no case was cell
death due to excessive confluence as confirmed by plate inspec-
tion with a microscope.
Propidium Iodide Incorporation—Cells were transiently
transfected with the desired combinations of cDNA constructs
and with GFP for the selection of the transfected population.
Cells were cultured in 0.1% FBS DMEM for 48 h. If required,
cells were treated with the PLC inhibitor U73122 (10 M) or
with the ERK5 inhibitor XMD8–92 (1M) 24 h before staining.
Cells were washed twice with PBS and resuspended in Staining
Buffer (PBS 1, 1% BSA, 0.01%NaN3, 1% FBS) with propidium
iodide (PI) 1 g/ml. Analysis was carried out in a BD FacsCali-
bur flow cytometer (BD-Bioscience) andGFP-positive and pro-
pidium iodide-positive cells were quantified using CellQuest
Software (BD-Bioscience) and analyzed with the FlowJo Soft-
ware. Within the GFP-positive population the percentage of
PI-positive cells was calculated as ameasure of cell death due to
heterologous expression.
Annexin V/7-AAD Binding—To quantitatively measure apo-
ptosis, the PE Annexin V Apoptosis Detection kit I (BD Biosci-
ence) was utilized. Transfection and serum starving were car-
ried out as in PI assays, after which cells were re-suspended in
FIGURE3.PKCdoesnotinteractwiththeclassicaleffector-bindingregionof
Gq.A, C terminus ofGq (aa222–353) is essential for the interactionwith PKC.
COS-7 cells were transfected with HA-PKC and two EE-tagged chimeras: Gi-
ctGq [Gi1(1–222)-Gq (223–253)] and Gq-ctGi [Gq (1–222)-Gi1 (223–
253)]. B and C, mutations in Gq impairing PLC/p63RhoGEF/GRK2-binding
enhance the interaction with PKC. COS-7 cells were transfected with HA-PKC
and different association-deficientmutants of Gq (R256A/T257Amutation dis-
rupts PLC (22) andp63RhoGEF (23) binding, and either Y261F orW263Dmuta-
tions disrupt GRK2 binding (24)). Cell lysates and HA-PKC immunoprecipitates
wereanalyzedbyWesternblot as in Fig. 2. Blots representativeof three indepen-
dent experiments are shown in all panels. In B and C, data (mean S.E. of three
independent experiments) were normalizedwith respect to control (*, p 0.05;
**, p 0.01 two tailed t test).
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Annexin V-binding buffer (0.1 M Hepes/NaOH (pH 7.4), 1.4 M
NaCl, 25 mM CaCl2) at a final concentration of 1  105 cells.
Samples were incubatedwith 2.5l of PEAnnexinV and 5l of
7-AAD for 15 min at RT in the dark. Subsequently, 400 l of
binding buffer was added, and samples were analyzed by flow
cytometry within 1 h on a BD FacsCalibur flow cytometer (BD-
Bioscience). To determine the apoptotic stage of the different
GFP-positive cell populations, 7-AAD- andAnnexinV-positive
cells were determined with the CellQuest Software (BD-Biosci-
ence) and analyzedwith the FlowJo Software. Cells treated with
staurosporine (2.5 M, 2 h) or ultraviolet irradiation (2 h), were
considered the apoptotic (annexin V-positive) and necrotic
(7-AAD-positive) controls, respectively. Within the GFP-posi-
tive population the percentage of annexin-positive cells was
calculated as a measure of apoptotic cell death due to heterol-
ogous expression.
Statistics—Statistical analysis was performed using the two-
tailed Student’s t test, as indicated in the figure legends.
Results
Gq/PKCComplex Formation in Vitro and in Living Cells—
The activation of the ERK5 pathway by Gq-GPCRs appears to
correlate with the formation of a transient complex between
Gq and PKC (8). Such interaction was suggested to be direct
since these purified proteins are able to associate in vitro. A
pull-down assay performed with purified proteins indicated
that PKC preferentially binds the GTPS-loaded form of Gq
(Fig. 1A). Further, the formation of a Gq/PKC complex in
living cells was assessed through a Protein-fragment Comple-
mentation Assay (PCA) (Fig. 1B). A clear association between
PKC and Gq was observed, as compared with a known high-
affinity interaction (GCN4 leucine “zipper” dimerization) (Fig.
1C). The Gq/PKC complex displays high specificity, since no
association was detected between Gq and another member of
the PKC family, PKC, nor between PKC and another mem-
ber of the G family (Gi1) (Fig. 1C).
The PB1 Domain of PKC Is Essential for Gq Association—
PB1 domains are known protein-protein interaction domains,
and thismodule alone accounts for themajority of the reported
interactions of PKC (15). PKC-PB1 domain overexpression
was shown to interfere with the formation of Gq/PKC com-
plexes in cells, as assessed through co-immunoprecipitation
assays (Fig. 2A). Indeed, the PKC-PB1 domain alone is able to
co-immunoprecipitate with Gq (Fig. 2B), thus suggesting that
PKCmight interact with Gq through this module.
FIGURE4.Gq interactswithPKC throughanoveleffector-bindingregion.A, cartoonof the switch II/III region inGqshowing thebindingsites forRGSproteins
andeffectors. ImportantresiduesforGqinteractionwithPLC,GRK2,p63RhoGEF,orRGSproteins ((22–24))arehighlighted.Aregionwithsequencesimilaritiestothe
PB1 domain type I of MEK5, was identified at the 4 strand/4-3 loop of Gq. Acidic residues in this region of Gq were mutated to alanine. B, mutations in the
(228–252) regionofGq interferewith PKCbinding. COS-7 cellswere transfectedwithHA-PKC and the indicatedGqmutants. Cell lysates andHA-PKC immuno-
precipitateswere analyzed as inprevious figures. Data (mean S.E. of three independent experiments)werenormalizedwith respect to PKC/Gqwt association (*,
p0.05; ***,p0.001 two tailed t test).C, sequenceanalysis of thePKCbinding region inGq.Glutamicacids234and245 (E234/E245)ofGqalignwith conserved
glutamic acids from PB1-type I proteins that form two clusters (A1 and A2) that are crucial for their function as a protein-protein interaction domain. Sequence
alignmentofdifferentPB1-type Idomainsandthe4-3 loopofGqwereperformedwithMultalin software.Sequence IDs:GNAQmouse (NP_032165),MEK5mouse
(Q62862), Sqstm1mouse (p62, NM_011018), PKCmouse (NM_001039079), PKC/i mouse (NM_008857).
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The PB1 domain of PKC is composed of a PB1-type I
(acidic) and a PB1-type II (basic) domain (16). Since the PB1-
type II domain of PKC has previously been involved in ERK5
activation by the EGF receptor and in MEK5 binding (17), a
strategy was designed to mutate key amino acids in this region
(Fig. 2C). In particular, lysine 19 (K19) seems to be an invariably
crucial residue in all PB1-PB1 interactions in combination with
other predominantly basic residues located nearby within the
three-dimensional structure (18, 19). Remarkably, different
point mutations in the PB1-type II region and specially that in
Lys-19 decreased the interaction with Gq in co-immunopre-
cipitation experiments (Fig. 2D). This residue was also found to
be essential for PKC-MEK5 binding (Fig. 2E), as predicted by
other PB1-PB1 structures (19). Interestingly, another mutation
within this domain (PKC-H21A) enhanced the ability of PKC
to associate withGq (Fig. 2F). Taken together, these data indi-
cate that the PB1 domain type II of PKC is crucial for binding
Gq.
FIGURE5.TheGq/PKC complex is involved inERK5activation.A, knockdownefficiencyupon transfectionof a scrambledor a specific shRNAagainst PKC
in CHO-M3 cells (see “Experimental Procedures”). B, PKC is required for ERK5 activation by a Gq-coupled GPCR. CHO-M3 cells were transfected with HA-ERK5,
Gq-wt, and either scrambled or PKC-targeting shRNA, serum-starved for 24 h and stimulated with carbachol (10 M) for 15 min. ERK5-HA was immunopre-
cipitated and analyzed by Western blot. Data (mean  S.E. of three independent experiments) were normalized with total ERK5 and expressed as fold-
induction of ERK5phosphorylation over control (*,p 0.05; two tailed t test).C, PKC is not required for ERK1/2 activationby aGq-coupledGPCR. CHO-M3 cells
transfected and stimulated as in panel B were tested for ERK1/2 activation. Representative blot of three independent experiments is shown. D and E, PKC
association-deficient Gq mutant cannot activate ERK5 in response to carbachol. CHO-M3 cells were transfected with HA-ERK5, pcDNA3, Gq or GqE234/
E245-AA (Gq-EEAA), serum-starved for 2 h and stimulatedwith carbachol (10M). InD, ERK5-HAwas immunoprecipitated andanalyzedbyWesternblot. Data
(mean S.E. of three independent experiments)werenormalizedwith total ERK5 andexpressed as fold-inductionof ERK5phosphorylationover control (*,p
0.05; ***,p0.001, two tailed t test). In E, ERK1/2 activationwas assessed in cell lysates as inpanel C. Data (mean S.E. of three independent experiments)were
normalized to pcDNA3 transfection (*, p 0,05, two-tailed t-Test). F andG, a constitutively active PKC association-deficient Gqmutant cannot activate ERK5
whereas it fully activates ERK1/2. CHO-M3 cells were transfected with empty vector (pcDNA3) or plasmids encoding HA-ERK5 (F) and the constitutively active
mutants Gq-R183C or Gq-R183C-E234/E245-AA (Gq-R183C-EEAA) (both panels F andG). Sampleswere processed and analyzed as inD–E (**, p 0.01, two
tailed t test; *, p 0.05, two tailed t test).
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A Novel Region in Gq Is Required for the Interaction with
PKC—Since members of the Gi family cannot interact with
PKC (Fig. 1C and Ref. 8), we utilized two different chimeras in
which the C terminus (aa 222–353) of either Gq or Gi1 had
been substituted by that of Gi1 and Gq, respectively (20), to
delineate relevant regions for PKC association. A Gq chi-
mera with the C terminus of Gi1 was unable to interact with
PKCwhen expressed in cells (Fig. 3A), thus suggesting that the
interaction determinants are predominantly located in the C
terminus of Gq. This C-terminal stretch includes the classical
effector-binding region (21). To assess whether this region is
responsible for binding PKC, we used different Gq mutants
unable to interact with other effectors such as PLC and
p63RhoGEF (Gq-R256A/T257A, (22, 23)) or GRK2 (Gq-
Y261F and Gq-W263D (24)). Surprisingly, neither mutant
affected PKC binding but on the contrary all co-immunopre-
cipitated with the kinase to a greater extent thanwild-typeGq
(Fig. 3, B and C). These data suggest that the absence of com-
petitors on the surface ofGq favors the interactionwith PKC.
This may indicate that PKC is interacting with other region
close to the classical effector site. We noted that the adjacent
4-3 loop inGq displays a relatively high sequence similarity
with the PB1-type I domain ofMEK5, amodule known to inter-
act with the PB1-type II domain of PKC (Fig. 4A). A double
mutation (E234/E245-AA) in the homologous residues of Gq
in this potential interaction module significantly impaired its
association with PKC (Fig. 4B). Interestingly, these amino
acids were found to be homologous to highly conserved resi-
dues in several PB1-type I domain-harboring proteins as part of
two major functional clusters (A1 and A2) (Fig. 4C) (18). Over-
all, these data indicate that a region of Gq, distinct from the
classical effector-binding site, is involved in the interactionwith
PKC.
An Efficient Gq/PKC Association Is Required for the Acti-
vation of the ERK5 Pathway—We previously suggested that
PKC is required for Gq-coupledGPCR activation of ERK5 (8, 9).
To confirm this, we silenced PKC in CHO-M3 cells (Fig. 5A) and
stimulated the cells with carbachol to reach maximum activation
as previously reported (25). Activation of ERK5 was abolished in
the absence of PKC (Fig. 5B), whereas ERK1/2 phosphorylation
was seemingly unaffected (Fig. 5C). To establish whether this
effect depends on the formation of a Gq/PKC complex, we
assessed the activation of ERK5 by the PKC-binding deficient
mutant (Gq-E234/E245-AA; Gq-EEAA hereafter) in response
to carbachol stimulation. Notably, overexpression of wild-type
Gqclearly enhancedERK5activationbyGPCRsas reported (25),
whereas the Gq-EEAA mutant did not (Fig. 5D). In the same
experimental setting thepromotionofERK1/2activationwas sim-
ilar upon eitherwild-typeGqorGq-EEAAexpression (Fig. 5E).
Consistently, the direct activation of ERK1/2 by constitutively
active Gq (R183C) was not affected by the EEAA mutation as
opposed to the activation of ERK5, which was impaired (Fig. 5, F
FIGURE6.Gq formsanactivation-dependent complexwithERK5 throughPKC.A andB, ERK5preferentially co-immunoprecipitates activeGq. CHO-M3
cells were transfected with HA-ERK5, Gq wt, Gq-R183C, or Gq-Q209L (constitutively active mutants) as indicated. Cell lysates and HA-ERK5 immunopre-
cipitates were analyzed as in previous figures. Representative blot of three independent experiments are shown. C, PB1 domain of PKC interferes with
Gq/ERK5 complexes. CHO-M3 cells were transfectedwith HA-ERK5, Gq-Q209L, and PKC-PB1 domain and ERK5 complexes analyzed as above (mean S.E.
of three independent experiments) (*, p  0.05). D, PKC silencing decreases the formation of Gq/ERK5 complexes. CHO-M3 cells were transfected with
HA-ERK5, Gq Q209L, and PKC-targeting shRNA, and ERK5 complexes quantified as in C. Data (mean  S.E. of three independent experiments) were
normalizedwith total ERK5 and expressed as fold-induction of co-immunoprecipitatedGqover shRNA scrambled (*,p 0.05; ***,p 0.001, two tailed t test).
E, ERK5 interacts directlywith PKC. FusionproteinsGST-ERK5 (100nM) andpurifiedGST (100nM) as negative controlwere incubatedwithHis-PKC (20 nM) and
mixtures analyzed as detailed under “Experimental Procedures.” A blot representative of two independent experiments is shown.
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and G). These results indicate that this mutant retains the ability
to modulate the activity of other Gq effector proteins and sup-
port the specificity of the Gq/PKC axis in promoting ERK5
activation.
PKC Scaffolds an Activation-dependent Gq/ERK5 Com-
plex—Interestingly, Gq was found to co-immunoprecipitate
with the activated form of ERK5 and this was clearly decreased
by the EEAA mutation (Fig. 6A). The formation of Gq/ERK5
complexes was greatly favored by activating mutations in the
G subunit (R183C or Q209L) (Fig. 6B), which supports the
formation of the complexes upon GPCR stimulation. We
hypothesized that PKC could be organizing a multimolecular
Gq/ERK5 complex uponGprotein activation. Both the co-ex-
pression of the PKC-PB1 domain or the down-regulation of
PKC expression led to a decreased formation of Gq/ERK5
complexes (Fig. 6, C and D). To address whether PKC could
exert a scaffold role through a direct interaction with ERK5, we
performed pull-down experiments with purified proteins and
found that PKC andERK5 are direct binding partners (Fig. 6E).
Although other authors have suggested the occurrence of this
complex (26), we provide the first concluding evidence for a
direct association. Collectively, our findings suggest that PKC
orchestrates a ternary complexwithGq and ERK5 that under-
lies the activation of the signaling cascade.
GRK2 Negatively Regulates the Gq/PKC Complex and
Receptor-induced ERK5 Activation—GRK2 is a negative regu-
lator of Gq signaling both through receptor desensitization
mechanisms and direct inhibition of Gq-effector interactions
(27). Consistently, we observed that overexpression of wild-
typeGRK2 completely abolishedGq association to PKC (Fig.
7A). Such effect was independent of GRK2 kinase activity
and mimicked by its RH domain, a region reported to specif-
ically interact with Gq (28). Also, a GRK2 mutant (D110A)
which is unable to interact with Gq (28) barely interfered
with formation of the Gq/PKC complex (Fig. 7B). The
negative regulation exerted by GRK2 was also detected in a
natural cell milieu, as assessed through the Venus-YFP PCA
(Fig. 7C). On the contrary, as observed for other Gq effec-
tors (29), PKC was not displaced by the Gq regulators
RGS2 or 4 (Fig. 7, D and E).
In agreement with the ability to inhibit Gq/PKC interac-
tion, enhanced GRK2 levels in CHO-M3 cells abolished carba-
chol-induced ERK5 activation (Fig. 8A). ERK5 activation was
reduced to50% upon expression of the RH domain of GRK2
(Fig. 8B), whereas a kinase-inactive GRK2-K220R mutant did
not disrupt ERK1/2 signaling as compared with wild-type
GRK2 (Fig. 8C). This suggests that direct Gq binding plays a
role in the attenuation of ERK5 signaling by GRK2 in addition
FIGURE 7. GRK2 is a negative regulator of the Gq/PKC complex. A, GRK2 overexpression impairs Gq/PKC association through its RH domain. COS-7
cells were transfected with HA-PKC and Gq along with GRK2 wild-type, GRK2 K220R (kinase-inactive mutant) or the GRK2 RH domain. Cell lysates and Gq
immunoprecipitates were analyzed by Western blot. B, Gq association-deficient GRK2 mutant does not interfere with the Gq/PKC complex. COS-7 cells
were transfected with Gq, HA-PKC, GRK2 wt, and the GRK2 D110A mutant, which has impaired ability to bind to Gq (25) and lysates and HA-PKC
immunoprecipitates analyzed as in previous figures. C, GRK2 overexpression impairs Gq/PKC association in living cells. HEK293 cells were transfected with
Venus YFP PCA plasmids: Control (PKC-Venus YFP[F1]pcDNA3), GqPKCpcDNA3 (Gq-Venus YFP[F1] PKC-Venus YFP[F2]pcDNA3),
GqPKCGRK2 (Gq-Venus YFP[F1] PKC-Venus YFP[F2]GRK2). Data (mean S.E. of three independent experiments)were normalizedwith respect to
control (**, p 0.005, two tailed t test). Bar length, 25m.D and E, RGS2/4 overexpression does not alter the formation of the Gq/PKC complex. COS-7 cells
were transfected with combinations of plasmids encoding HA-PKC, Gq, and RGS2 or RGS4. Either Gq (D) or HA-PKC (E) immunoprecipitates and total
lysates were analyzed as above. In all panels, blots shown are representative of 2–3 independent experiments.
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to kinase-dependent GPCR desensitization. Consistently, the
duration and amplitude of carbachol-induced ERK5 activation
(Fig. 8D), as well as the assembly of Gq/ERK5 multimolecular
complexes (Fig. 8E) were markedly enhanced when expressing
a GRK2 binding-deficient mutant of Gq (Gq-Y261F).
Gq Is Involved in Apoptotic Cell Death Promotion via
PKC—The description of PKC as an effector protein for Gq
suggested that it might underlie specific cellular functions pro-
moted by the G protein. Since cell death promotion is a well-
establishedGq-initiated process ((21) and references therein),
we compared cell viability in CHO cells expressing Gq wt or
the Gq-EEAA mutant upon long-term growth in low serum
(3% FBS). Cell death took place earlier in Gq-overexpressing
cells compared with control and Gq-EEAA populations, both
of which initiated this process in a similar timeframe (Fig. 9A).
The clear increase in cell death promoted by a constitutively
active Gq mutant (Gq-R183C) was attenuated when intro-
ducing the EEAAmutation (which reduces the interactionwith
PKC) and, contrarily, it was enhanced by the Y261F mutation
(that potentiates the PKC interaction) (Fig. 9B), consistent
with a role for the Gq/PKC signaling axis in triggering this
process. Such impaired ability of theGq-EEAAmutant to pro-
mote cell death was also observed in HeLa cells (data not
shown). Moreover, cell death upon constitutively active Gq
overexpression in CHOcells was neither affected by amutation
that impairs PLC activation (R256/T257-AARef. 22) (Fig. 9C)
nor by PLCpharmacological inhibition (Fig. 9D).On the other
hand, either ERK5 inhibition or co-expression of the PB1
domain of PKC showed an inhibitory effect on Gq-induced
cell death (Fig. 9D), suggesting that this Gq-initiated process
is, at least in part, dependent on PKC-mediated activation of
ERK5.The phenotype observedwas determined to be apoptotic
cell death, as both annexin V staining and caspase 3 cleavage
were enhanced upon Gq-R183C overexpression and abro-
gated by the EEAA mutation (Fig. 9, E and F). Taken together,
these data reveal that the novel binding region of Gq is
involved in the promotion of apoptotic cell death via PKC.
Discussion
Emerging evidence indicates that activatedGq subunits can
interact with several effector proteins to trigger signaling path-
ways different from the canonical PLC cascade. Previously, we
reported a direct, activation-dependent association between
Gq and PKC in the context of Gq-coupled GPCR-mediated
activation of ERK5 (8). These data suggested a genuine G pro-
tein-effector interaction although a causal relationship be-
tween the formation of a Gq/PKC complex and Gq-depen-
dent functional outputs remained to be established. Herein we
provide conclusive evidence showing that PKC acts as a Gq
effector through the engagement of a novel binding region in
the  subunit leading to ERK5 activation and apoptotic cell
death.
First, we show that the basic PB1-type II domain of PKC,
governed by the Lys-19 residue, is critical for the association
with Gq. This region was found to mediate protein-protein
interactions of PKC that are involved in NFB activation or
FIGURE 8. GRK2 is a negative regulator of Gq-GPCR-mediated ERK5 activation. A, GRK2 overexpression abolishes ERK5 activation by the Gq-coupled M3
receptor. CHO-M3 cells were transfected with empty vector (pcDNA3), HA-ERK5, and GRK2, serum-starved and stimulated with carbachol (10 M). ERK5
stimulation was assessed as in Fig. 5 (mean S.E. of three independent experiments) (*, p 0.05; two tailed t test). B, GRK2 RH domain overexpression
partially abolishes ERK5 activation by the Gq-coupled M3 receptor. CHO-M3 cells were transfected with HA-ERK5 and pcDNA3, GRK2 wt or the GRK2-RH
domain. Samples were processed as above for ERK5 activation. Blots shown are representative of two independent experiments and display the
calculated fold-induction. C, Gq-GPCR-triggered ERK1/2 activation is not affected by a kinase-deficient GRK2 mutant. CHO-M3 cells were transfected
with Gq and either pcDNA3, GRK2, or GRK2-K220R, and treated as above followed by analysis of ERK1/2 activation. Data were normalized to pcDNA3
transfection. Blot is representative of four independent experiments and display the calculated fold-induction. D, a GRK2 association-deficient Gq
mutant enhances ERK5 activation. CHO-M3 cells were transfected with HA-ERK5 and either Gq wt or Gq Y261F (deficient in GRK2 binding) and
processed as in A (**, p  0.005; ***, p  0.001, two tailed t test). E, Gq mutant with diminished GRK2-association ability shows increased co-
immunoprecipitation with ERK5. CHO-M3 cells were transfected with HA-ERK5 and either Gq wt or Gq-Y261F. Cell lysates and HA-ERK5 immunopre-
cipitates were analyzed. Data (mean S.E. of three independent experiments) were normalized with respect to ERK5/Gq wt co-immunoprecipitation
(***, p  0.001).
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cell polarity establishment (30), and also in ERK5 activation by
EGF (17). Our finding is consistent with the fact that indepen-
dent expression of the PKC PB1 domain inhibited Gq-GPCR-
mediated ERK5 stimulation (8). Second, we describe a novel
binding region inGq driving the interaction with PKCwhich
is different from the classical effector-binding region and shows
surprising sequence similarities to PB1-type I domains.
Overall, the fact that the PKC interaction residues inGq lie
in the vicinity of the classical effector-binding region, supports
our conclusion that PKC is a bona-fide effector of Gq that
associateswith a subset of amino acids that are distinct from the
binding determinants of other Gq binding partners (PLC,
GRK2, andp63RhoGEF). All effectors ofG subunits invariably
associate with the extended region comprising the C-terminal
half of the 2 helix, together with the 3 helix and its junction
with the 5 strand, although the subsets of crucial amino acids
for these associations vary with the specific effector (31). Inter-
estingly, residues 221–245 of Gq, which include the PKC-
binding region but not the classical effector-binding residues,
has been recently identified to mediate association with the
cold-activated channel TRPM8, a novel Gq interaction part-
ner (32). This supports the characterization of this Gq region
as a functional module capable of binding different cellular
proteins.
Our data show that Gq strictly depends on the association
with PKC to promote ERK5 activation. Indeed, the EEAA
FIGURE 9. The Gq/PKC complex is involved in apoptotic cell death. A, PKC-association impairing mutations abolish Gq-induced cell death. CHO-M3
cells were transfectedwith GFP and either pcDNA3 empty vector, Gqwild-type, or the Gq-E234/E245-AA (Gq-EEAA)mutant. GFP-positive cells were sorted,
seeded onto 96-well sensor plates and monitored with the X-Celligence system for over 140 h. Cell death entry time was determined as the inflection
point at which the cell index shifts to negative values (see “Experimental Procedures”). Data were the mean S.E. of five independent experiments (*,
p  0.05, two tailed t test). B, constitutively active Gq mutants with diminished (EEAA) or enhanced (Y261F) PKC association ability decrease and
increase cell death, respectively. CHO-M3 cells were transfected and cultured in 0.1% FBS for 48 h. The proportion of transfectants (GFP-positive cells)
that show propidium iodide-positive staining was determined through flow cytometry (mean S.E. of three independent experiments) (*, p 0.05; ***,
p  0.001, two tailed t test over pcDNA3; #, p  0.05 over Gq-R183C). C, Gq mutation that impairs PLC activation does not affect cell death
promotion. PI-positive cells were determined in populations overexpressing constitutively active Gq (Gq-R183C or Gq-Q209L) or a mutant with
impaired PLC activation (Gq-Q209L-R256/T257-AA) and expressed as fold over Gq-R183C-transfected cells. D, Gq-induced cell death is decreased
by PKC-PB1 domain overexpression or by an ERK5 inhibitor (XMD8–92), but not by a PLC inhibitor (U73122). PI-positive cells were quantified as before
in populations overexpressing Gq-R183C and treatedwith the indicatedmodulators (*, p 0.05; ***, p 0.001, two tailed t test over Gq-R183C). E and
F, PKC-association impairing mutations abolish constitutively active Gq-induced apoptosis. Assays were carried out as above. GFP-positive cells that
show annexin V staining were measured by flow cytometry and the data are expressed as fold over empty vector-transfected cells (mean S.E. of three
independent experiments) (***, p 0.001; two tailed t test over pcDNA3). Cleaved caspase-3 was detectedwith a specific antibody (mean S.E. of three
independent experiments) (**, p  0.005; two tailed t test with respect to Gq-R183C). Representative Western blots to confirm the expression of the
different plasmids in the experiments are shown.
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mutation in Gq abrogated both direct and receptor-induced
ERK5 phosphorylation, whereas ERK1/2 activation remained
unaffected. Importantly, we demonstrate that Gq and ERK5
are found together in an activation-dependent multimolecular
complex orchestrated through PKC scaffolding, which di-
rectly binds ERK5 and enables the stimulation of the pathway.
This scaffold rolewas supported by the finding thatGq-coupled
GPCRs do not promote phosphorylation-dependent activation
of PKC (8). Instead we observed (data not shown) that carba-
chol induces dimerization of the kinase at a coincident time-
course to the Gq-PKC interaction. This could be relevant
since dimerization not only is a common scaffold protein
mechanism but, in the case of PB1-PB1 associations, it has
recently been shown to promote PKC activation independent
of phosphorylation (33). Indeed, Par6 interaction with PKC
induces its allosteric activation through the displacement of the
PKC pseudo-substrate region from the active site (33). Inter-
estingly, Gq-mediated activation of effectors PLC (34) or
p63RhoGEF (23) involves the allosteric relief of an auto-inhib-
itory loop buried within the active region. Thus, it is possible
that a PB1-domain-dependent relief of pseudo-substrate auto-
inhibition in PKC could be induceduponGqbinding or upon
GPCR-induced dimerization. It is tempting to suggest that
PB1-drivenPKC scaffoldingmight be a cellularmechanism for
imposing spatial and temporal specificity during Gq-initiated
signaling.
The regulation of Gq/effector complexes byGRK2 is a well-
established process for dampening downstream signaling. We
show that GRK2 impedes the association of PKC with Gq in
living cells, and abrogates ERK5 activation due to G protein
sequestering and receptor desensitization, as reported for other
Gq/effector complexes (35). Coincidently, we show that the
impairment of the GRK2/Gq interaction with a specific asso-
ciation-deficient Gq mutant (Y261F) greatly enhances Gq
interaction with PKC and its presence in ERK5 complexes,
thus promoting ERK5 activation. These findings strengthen the
role of PKC as a novel Gq effector and suggest that Gq
signaling toward the PKC/ERK5 pathway could be effectively
modified in pathophysiological contexts where GRK2 expres-
sion and/or functionality is altered (36).
Finally, we put forward the assembly of Gq/PKC com-
plexes as an important process for the promotion of apoptotic
cell death by Gq. The increase in cell death promoted by the
presence of constitutively-active Gq was abolished by the
EEAA mutation (which blocks the assembly of Gq/PKC
complexes), so cells expressing the Gq-EEAA mutant dis-
played a higher viability than those expressing Gq wild-type.
On the contrary, the presence of the GRK2-association defi-
cient Gq mutation Y261F (leading to increased complex for-
mation) potentiated cell death. This process is conserved in
HeLa cells, and was characterized as apoptosis-mediated cell
death, consistent with the reported role for Gq in the promo-
tion of apoptosis (37). In line with the notion that PKC is as a
key effector in this process, the overexpression of the PKC
-PB1domain decreasedGq-promoted cell death,whereas nei-
ther PLC inhibitors nor Gq mutants that cannot activate
PLC have an effect. These results are in agreement with pre-
vious reports showing that caspase activation and apoptosis
promoted by activated Gq is not blocked by inhibitors of IP3-
or PKC-dependent signaling (38). Also, the role of PKC as a
pro-apoptotic protein appears to have a crucial effect on the
repression of tumorigenesis in ovarian (39) and prostate cancer
(40). Interestingly, pharmacological blockade of ERK5 partly
inhibited cell death promotion downstream of the Gq/PKC
axis. Although ERK5 is a well-known pro-survival factor in sev-
eral contexts (41), it also has been shown to positively regulate
apoptosis of medulloblastoma cells (42) and thymocytes (43).
However, we cannot rule out that, alongside ERK5, other yet
unidentified pathways downstream the Gq/PKC axis would
play a role in this process.
In sum, we propose the following mechanistic model for the
Gq/PKC axis (Fig. 10): Ligand binding to the receptor causes
Gq activation (step 1) which, in turn, promotes the interaction
between the PB1 domain type II of PKC and the novel effector-
binding region of Gq-GTP (step 2). This would lead to PKC
allosteric activation, dimer/oligomerization and to the expo-
sure of its kinase domain to interact with ERK5, which is
recruited into a multimolecular complex together with Gq
(step 3). Next, MEK5 would be attracted into an intermediate
signaling complex through a direct interaction with Gq (8)
which would rapidly progress into MEK5 displacing Gq from
its binding site on PKC (step 4). Subsequently, the interaction
between MEK5 and PKC would favor the autophosphoryla-
tion of MEK5, which will, in turn, phosphorylate and activate
ERK5 (step 5) (17). Additionally, GRK2 and RGS proteins
would act as negative modulators of this cascade by sequester-
ing Gq away from PKC (step 2), or by binding to Gq in
complex with PKC to promote GTPase activity and deactiva-
tion of the G  subunit (step 3), respectively. Finally, we pos-
tulate that the promotion of apoptotic cell death may depend
both on ERK5 and other yet uncharacterized targets down-
stream the Gq/PKC complex. This model may serve as a
theoretical framework for subsequent studies of this signaling
axis and contribute to revise the functional consequences of
Gq activation.
FIGURE 10. Mechanistic model for the activation of the Gq/PKC/ERK5
axis by Gq-coupled GPCRs. Proposed sequential formation of protein com-
plexes involved in the Gq-ERK5 pathway. See text for detailed information.
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